Results 151 to 160 of about 338,332 (265)
AI‐Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint
AI‐designed cyclic peptides enable controllable modulation of the CD28 immune checkpoint through reversible disruption of CD28‐CD80/CD86 interactions. The lead peptide, CIP‐3, suppresses T‐cell activation without intrinsic agonist activity, demonstrates dose‐dependent efficacy in a murine colitis model, and attenuates inflammatory cytokine production ...
Katarzyna Kuncewicz +4 more
wiley +1 more source
LAG Time in the Era of Immunotherapy-New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene-3. [PDF]
Luca VC.
europepmc +1 more source
An edible biohybrid platform triggers nanoplastics (NPs) aging and agglomeration by in situ generating hydroxyl radicals within the intestine. The enlarged NPs are unable to penetrate the intestine and are subsequently excreted. Simultaneously, probiotic biofilms reinforce the intestinal barrier.
Su Zhou +4 more
wiley +1 more source
This study unveils an unrecognized pro‐inflammatory epitranscriptomic checkpoint in psoriasis. By installing m7G modifications on the 5′ UTR of Bdkrb1 mRNA, METTL1 enhances receptor stability to orchestrate keratinocyte‐driven neutrophil recruitment via p38 MAPK signaling.
Chang Zhang +10 more
wiley +1 more source
Exploring the molecular landscape of lymphocyte activation gene-3: A literature review. [PDF]
Nie J, Qin X, Tao X, Huang J.
europepmc +1 more source
CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen +12 more
wiley +1 more source
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. [PDF]
Ren K, Hamdy H, Meyiah A, Elkord E.
europepmc +1 more source
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai +12 more
wiley +1 more source
Interleukin-18 Binding Protein (IL-18BP) Deficiency Affects Lymphocyte Activation and IL-18 Expression in a Mouse Model of Liver Inflammation. [PDF]
Devisme C +7 more
europepmc +1 more source

